Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fibrogen Inc CS (NQ: FGEN )

0.4745 +0.0345 (+7.84%)
Streaming Delayed Price Updated: 2:03 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fibrogen Inc CS

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
NASDAQ: FGEN Long Term Investor Alert: Investigation of Potential Wrongdoing at FibroGen, Inc.
San Diego, CA -- (SBWIRE) -- 08/20/2021 -- An investigation on behalf of current long term investors in FibroGen, Inc. (NASDAQ: FGEN) shares over possible breaches of fiduciary duty by certain officers... 
Via SBWire
Topics Lawsuit
Exposures Financial Legal Product Safety
38 Stocks Moving In Friday's Mid-Day Session
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares climbed 45.8% to $6.27 after the company presented data from ongoing studies of its preventive vaccine against COVID-19, showing... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For August 20, 2021
Upgrades For Investors Bancorp Inc (NASDAQ: 
Via Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by... 
Via Benzinga
Exposures Product Safety
Here's What Recent News From the FDA Means for AstraZeneca
Even though AstraZeneca and FibroGen must now conduct an additional safety trial to have a chance at FDA approval, not all is lost. 
Via The Motley Fool
Exposures Product Safety
22 Stocks Moving in Friday's Pre-Market Session
Gainers GeoVax Labs, Inc.. (NASDAQ: GOVX) shares rose 72.1% to $7.40 in pre-market trading after the company announced it presented COVID-19 vaccine data at the European Society... 
Via Benzinga
Exposures COVID-19
A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings; Crude Oil Edges Lower
Pre-open movers U.S. stock futures traded lower in early pre-market trade after closing mixed in the previous session. Investors are awaiting earnings results from Deere &... 
Via Benzinga
Exposures Fossil Fuels
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
The FDA has issued a complete response letter regarding the marketing application for FibroGen Inc's (NASDAQ: FGEN) roxadustat for anemia of chronic kidney disease... 
Via Benzinga
Exposures Product Safety
10 Biggest Price Target Changes For Tuesday
Rosenblatt raised the price target on The Trade Desk, Inc. (NASDAQ: 
Via Benzinga
FibroGen, inc (FGEN) Q2 2021 Earnings Call Transcript
FGEN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
FDA approval of roxadustat seems unlikely. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis Product Safety
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
Week In Review: Qiming Launches $500 Million Fund For Listed Healthcare Companies
Qiming, a prominent China-based venture capital firm, has raised more than $500 million to invest in shares of listed healthcare companies. The Springhill Fund, as it is called, will have an initial... 
Via Talk Markets
FibroGen Out-Licenses Recombinant Human Collagen-Based Biosynthetic Cornea
Eluminex Biosciences (Suzhou) Limited has exclusively licensed global rights to develop and commercialize a biosynthetic cornea from FibroGen Inc (NASDAQ:... 
Via Benzinga
50 Biggest Movers From Friday
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 41.2% to settle at $7.10 on Friday. Blue Foundry Bancorp (NASDAQ: BLFY) gained 29% to close at $12.90 after the... 
Via Benzinga
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears,... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week... 
Via Benzinga
Exposures Product Safety
Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; Aehr Test Systems Shares Spike Higher
Toward the end of trading Friday, the Dow traded down 0.63% to 34,766.06 while the NASDAQ fell 0.47% to 14,475.13. The S&P also fell, dropping 0.53% to 4,336.88. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Here's Why FibroGen Stock Is Plunging Today
An FDA advisory committee made it clear that they don't want the agency to approve roxadustat due to safety concerns. 
Via The Motley Fool
Exposures Product Safety
Stocks Reverse Gains as Inflation Fears Weigh
Stocks reversed earlier gains brought on by strong retail sales data and mixed earnings reports, as worse-than-expected inflation findings weighed on Wall Street. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.